Research programme: TRAIL receptor 2 agonist - AffymaxAlternative Names: TRAIL R2 research programme - Affymax; Tumour necrosis factor-related apoptosis-inducing ligand receptor-2 - Affymax
Latest Information Update: 27 Aug 2009
At a glance
- Originator Affymax
- Class Peptides
- Mechanism of Action TRAIL receptor 2 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Jun 2005 Preclinical trials in Cancer in USA (unspecified route)